Nimodipine

Generic Name: Nimodipine

Brand Names: Nimotop, Nymalize

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₂O_₇

CAS Number: 66085-59-4

Unique Ingredient Identifier: 57WA9QZ5WH

Background: Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compare...

Indication: For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.

Associated Conditions: Delayed Ischemic Neurological Deficit

Associated Therapies: -

Clinical Trials

Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage

Phase 2

Withdrawn

Conditions: Acute Cerebrovascular Accident
Vasospasm

Interventions: Drug: Acetazolamide
Drug: Nimodipine

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-24

Lead Sponsor: University of Florida

Registration Number: NCT02165644

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

Phase 1

Completed

Conditions: Ruptured Cerebral Aneurysm
Ruptured Berry Aneurysm

Interventions: Drug: Nimodipine Microparticles
Drug: Nimodipine

First Posted Date: 2013-07-08

Last Posted Date: 2018-02-05

Lead Sponsor: Edge Therapeutics Inc

Target Recruit Count: 73

Registration Number: NCT01893190

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇨🇦
University Health Network - Toronto General Division, Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
Columbia University, New York, New York, United States

and more 20 locations

Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations

Phase 1

Completed

Conditions: Progranulin Mutation Carriers

Interventions: Drug: Nimodipine

First Posted Date: 2013-04-19

Last Posted Date: 2016-05-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT01835665

Locations: 🇺🇸
UCSF Memory and Aging Center, San Francisco, California, United States

Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT

Not Applicable

Completed

Conditions: Polycystic Ovarian Syndrome
Anovulatory
Unexplained Infertility

Interventions: Drug: Placebo
Drug: Nimodipine

First Posted Date: 2012-08-27

Last Posted Date: 2020-08-11

Lead Sponsor: Boston IVF

Target Recruit Count: 18

Registration Number: NCT01672801

Locations: 🇺🇸
Boston IVF, Waltham, Massachusetts, United States

Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients

Phase 2

Terminated

Conditions: Infertility

Interventions: Drug: Placebo
Drug: Nimodipine

First Posted Date: 2012-03-12

Last Posted Date: 2019-03-08

Lead Sponsor: Mount Sinai Hospital, Canada

Target Recruit Count: 12

Registration Number: NCT01551368

Locations: 🇨🇦
Toronto Centre for Advanced reproductive Technology (TCART), Toronto, Ontario, Canada

Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes

Phase 4

Conditions: Stroke
Mild Cognitive Impairment

Interventions: Drug: Nimodipine
Drug: Placebo

First Posted Date: 2010-10-14

Last Posted Date: 2010-10-14

Lead Sponsor: Ministry of Science and Technology of the People´s Republic of China

Target Recruit Count: 656

Registration Number: NCT01220622

Locations: 🇨🇳
Beijing Tian Tan Hospital, Capital Medical University, Beijing, China

The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Phase 4

Completed

Conditions: Dementia

Interventions: Drug: Galantamine
Drug: Placebo
Drug: Nimodipine

First Posted Date: 2008-12-25

Last Posted Date: 2013-08-26

Lead Sponsor: Janssen-Cilag Farmaceutica Ltda.

Target Recruit Count: 22

Registration Number: NCT00814658

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

Phase 4

Terminated

Conditions: Depression

Interventions: Drug: Nimodipine
Drug: Placebo

First Posted Date: 2008-10-29

Last Posted Date: 2016-09-29

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 9

Registration Number: NCT00781326

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1

Phase 1

Completed

Conditions: AIDS Dementia Complex
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000738

Locations: 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States

and more 9 locations

Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia

Not Applicable

Completed

Conditions: Pre-eclampsia

First Posted Date: 1999-10-19

Last Posted Date: 2015-03-25

Lead Sponsor: FDA Office of Orphan Products Development

Target Recruit Count: 2000

Registration Number: NCT00004399

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy